You are here: Industry Insights > CF

News List

European Commission approves cystic fibrosis treatment for six to 11-year-olds pharmatimes
January 11, 2022
There is currently no cure for cystic fibrosis (CF), a debilitating, progressive condition with over 10,830 people in the UK currently diagnosed with the disease.
Opportunities remain to address unmet needs in cystic fibrosis therapeutics market: GlobalData expresspharma
July 05, 2021
CFTR modulators are currently the only available treatments that target the underlying cause of CF. However, some patients with rare CFTR mutations are still ineligible to receive currently marketed therapies.
Unmet needs and opportunities in the cystic fibrosis market pharmaceutical-technology
July 05, 2021
The cystic fibrosis (CF) therapeutics market has a considerable number of unmet needs. GlobalData’s upcoming CF report indicates key unmet needs in this space including the lack of curative therapies, low patient adherence to treatment, limited choice ...
First-of-Its-Kind Study Uses Smartphone to Track Cystic Fibrosis in Real Life firstwordpharma
June 03, 2021
Today, the Cystic Fibrosis Foundation announced the initiation of the HERO-2: Home Reported Outcomes Study, a first-of-its-kind, at-home observational study that aims to characterize the range of outcomes people experience while using Trikafta®
EMA, MHRA to review Vertex' Kaftrio for children with CF pharmatimes
May 21, 2021
The European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have validated Vertex' applications to expand the scope of its cystic fibrosis (CF) treatment Kaftrio (ivacaftor/tezacaftor/elexacaftor).
Triple combo cystic fibrosis therapy Kaftrio scores EU label expansion pharmatimes
April 30, 2021
The European Commission (EC) has approved a label extension for Vertex’s triple combination cystic fibrosis (CF) treatment Kaftrio, extending its use for the ‘majority’ of patients aged 12 years and older in Europe.
Symkevi/Kalydeco cleared for use in young CF patients pharmatimes
November 30, 2020
The European Commission as approved use of Vertex' Symkevi (tezacaftor/ivacaftor) with Kalydeco (ivacaftor) for eligible children with cystic fibrosis (CF) aged 6-11 years.
Top 20 global pharma companies by MCap saw 10.2 per cent rise in MCap in Q2 2020: GlobalData expresspharma
September 24, 2020
Johnson & Johnson maintained its top position with MCap growth of 7.2 per cent on a QoQ basis.
EU nod for Vertex CF therapy Kaftrio pharmatimes
August 24, 2020
Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor) has been approved by the European Commission for use in combination with ivacaftor to treat people aged 12 years and older with certain forms of cystic fibrosis.
Vertex and NHS Wales agree on Kaftrio reimbursement pharmatimes
July 23, 2020
People with cystic fibrosis (CF) living in Wales should get speedy access to Vertex' new therapy following its approval by Europe regulators.

Previous page 1 2 Next page